2022-502716-37-00招募中2 期
A PHASE 2 STUDY EVALUATING INCB099280 IN PARTICIPANTS WITH SELECT SOLID TUMORS WHO ARE IMMUNE CHECKPOINT INHIBITOR–NAÏVE
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- Incyte Corp.
- 入组人数
- 70
- 试验地点
- 18
- 主要终点
- Objective response, defined as having a best overall response of confirmed CR or PR by investigator assessment per RECIST v1.1.
研究概览
简要总结
To determine the safety, tolerability, and preliminary efficacy of INCB099280 400 mg BID, 600 mg BID, and 800 mg BID in participants with advanced solid tumors.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Ability to comprehend and willingness to sign a written ICF for the study.
- •Age 18 years or older inclusive at the time of signing the ICF.
- •Prior systemic therapy, diagnoses, and disease settings as follows: a. Immunotherapy naive b. Measurable disease per RECIST v1.1 c. One of the following disease settings: see protocol
- •ECOG performance score of 0 or 1 (except for UC, where a score of up to 2 is permitted).
- •Life expectancy > 3 months
- •Willingness to avoid pregnancy or fathering children
排除标准
- •Known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of disease recurrence for 3 years since initiation of that therapy.
- •Presence of gastrointestinal conditions that may affect drug absorption, as well as those that interfere with gastrointestinal transit
- •Any autoimmune disease requiring systemic treatment in the past 5 years, including corticosteroids of a daily dose exceeding 10 mg of prednisone or equivalent
- •Diagnosis of primary immunodeficiency or receiving chronic systemic steroid therapy at a daily dose exceeding 10 mg of prednisone or equivalent
- •HIV infection and any one or more of the following: CD4+ T-cell count < 200 cells/µL, detectable viral load per parameters of assay, or antiretroviral therapy regimen containing moderate or potent CYP3A4/CYP3A5 inhibitors or inducers
- •Active infection requiring systemic therapy, with the exception of HIV and hepatitis
- •History of organ transplantation, including allogeneic stem cell transplantation.
- •Known hypersensitivity or severe reaction to any component of study drug or formulation components.
- •Postoperative complications preventing the participant from adhering protocol assessments and procedures.
- •Receipt of systemic antibiotics within 28 days of first dose of study treatment.
- •Probiotic usage is prohibited during screening and throughout the study treatment period.
- •CNS metastases requiring treatment and/or leptomeningeal disease.
- •Received a live vaccine within 28 days of the planned start of study drug. Note: Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, some shingles, yellow fever, rabies, BCG, and typhoid vaccines. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines are live-attenuated vaccines and are not allowed. Note: If enrolled, participants should not receive live vaccine during the study and up to 28 days after the last dose of study drug.
- •Treatment with moderate and potent CYP3A4/CYP3A5 inhibitors or inducers
- •Unable to be weaned off of a prohibited medication before the initiation of study treatment.
- •Participants with laboratory values at screening as defined in the protocol
- •Clinically significant ECG abnormality, including average QTcF interval > 480 milliseconds
- •Active HBV or HCV as follows (testing must be performed): a.Detectable HBV DNA (viral load) and HBsAg. b. Participants with chronic HBV infection with active disease who meet the criteria for anti-HBV therapy are required to be on a suppressive antiviral therapy prior to initiation of study treatment. c. Active HCV is defined as a positive HCV antibody result and quantitative HCV RNA (viral load) result greater than the lower limit of detection
- •Pregnant, expecting to conceive, or breastfeeding or expecting to father children
- •Any condition that would, in the investigator's judgment, interfere with full participation in the study
- •The following participants are excluded in France: vulnerable populations according to article L.1121-6 of the French Public Health Code and adults under legal protection, or who are unable to express their consent per article L.1121-8 of the French Public Health Code, not affiliated to a social security per article L.1121-8-1 of the French Public Health Code.
- •Toxicity from prior therapy that has not recovered to ≤ Grade 1 or baseline
- •Prior receipt of an anti–PD-1, anti–PD-L1, or anti–PD-L2 agent or treatment with an immune modulator
- •Received thoracic radiation of > 30 Gy within 6 months of the first dose of study treatment.
- •Participation in another interventional clinical study while receiving INCB
- •Treatment with anticancer medications or investigational drugs within the detailed intervals before the first administration of study drug
- •Impaired cardiac function or clinically significant cardiac disease
- •History or evidence of interstitial lung disease including noninfectious pneumonitis.
结局指标
主要结局
Objective response, defined as having a best overall response of confirmed CR or PR by investigator assessment per RECIST v1.1.
Objective response, defined as having a best overall response of confirmed CR or PR by investigator assessment per RECIST v1.1.
Incidence of TEAEs, assessed by physical examinations, changes in vital signs and ECGs, and analysis of clinical laboratory samples.
Incidence of TEAEs, assessed by physical examinations, changes in vital signs and ECGs, and analysis of clinical laboratory samples.
Incidence of TEAEs leading to dose interruption, dose reduction, or study drug discontinuation.
Incidence of TEAEs leading to dose interruption, dose reduction, or study drug discontinuation.
次要结局
- Disease control, defined as having a best overall response of confirmed CR or PR, or SD, after a minimum of 15 weeks following the initiation of study treatment by investigator assessment per RECIST v1.1.
- DOR, defined as the time from the earliest date of confirmed CR or PR to the earliest date of disease progression by investigator assessment per RECIST v1.1 or death due to any cause if occurring sooner than progression.
- TTR, defined as the time from the date of first dose to the earliest date of confirmed CR or PR by BICR per RECIST v1.1 or composite criteria for metastatic cSCC and WHO criteria for locally advanced cSCC.
- PFS, defined as the time from the date of first dose to the earliest date of disease progression by BICR per RECIST v1.1 or composite criteria for metastatic cSCC and WHO criteria for locally advanced cSCC or death due to any cause if occurring sooner than progression.
- OS, defined as the time from the date of first dose to death due to any cause.
- INCB099280 concentration in plasma.
研究者
Clinical Trial Information
Scientific
Incyte Corp.
研究点 (18)
Loading locations...
相似试验
招募中
2 期
A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma2022-502476-23-00Incyte Corp., Incyte Corp.97
招募中
2 期
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in participants with Parkinson’s Disease (LUMA)Parkinson's Disease2023-505645-12-00Biogen Idec Research Limited311
招募中
2 期
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) (FUSION)2022-502552-31-00Biogen Idec Research Limited195
已完成
2 期
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation2023-503223-26-00Incyte Corp.75
尚未招募
不适用
A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome.NCT07266324Bright Minds Biosciences Pty Ltd16